Osimertinib plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD.
Clin Cancer ResOct 1, 2026
Sarah B Goldberg, Myung-Ju Ahn, Christina Baik et al.
✦ AI-curated · Sources linked
In 30 seconds
The ORCHARD study was a phase II trial assessing the efficacy of osimertinib plus gefitinib in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) and EGFR C797X mutation after progression on first-line osimertinib. Among 31 evaluable patients, the confirmed objective response rate was 26%, with a median overall survival of 19 months.
Key findings
- Confirmed objective response rate was 26% (80% CI, 16-39).
- Median progression-free survival was 5.1 months (95% CI, 3.9-6.8).
- Median overall survival was 19 months (95% CI, 14.6-25).
- 35% of patients experienced grade ≥3 adverse events.
Why it matters
Understanding the effectiveness of combination therapies in resistant EGFR-mutated NSCLC is crucial for optimizing treatment strategies and managing patient outcomes in this challenging population.
What to keep in mind
The study's findings indicate that further evaluation of this regimen is not warranted in this population.